Objective: The objectives of this study are to define the specificity of the fusion transcript for the fibrolamellar subtype of hepatocellular carcinoma (FL-HCC) by testing a targeted sampling of other hepatic neoplasms/proliferations and extrahepatic neoplasms seen in children and young adults and to develop a FISH assay using a commercially available break apart probe for use in a CLIA-certified clinical laboratory.
Methods: Formalin fixed paraffin embedded tissue sections from 12 FL-HCC cases, 142 cases of other hepatic neoplasms/proliferations (conventional HCC, focal nodular hyperplasia (FNH), hepatocellular adenoma (HA) and hepatoblastoma (HB)) and extrahepatic neoplasms (neuroblastoma (NB), Wilms tumor (WT) and Gastrointestinal neuroendocrine tumor (GNET)) and 60 matched background normal control tissues underwent fluorescence in situ hybridization (FISH) testing using a break apart probe targeting the gene locus on chromosome 19 using standard techniques.
Results: The gene rearrangement was detected in 11/12 (92%) FL-HCC cases and 1/94 (1%) of conventional HCC cases. All other cases and background control tissues were negative for the gene rearrangement. These findings establish a test sensitivity of 91.7% and specificity of 99.5%.
Conclusion: This study shows that, using standard techniques, FISH testing with a commercially available break apart probe targeting the gene can be used as a surrogate for the fusion commonly found in FL-HCC. Also, the gene rearrangement is not expressed in other hepatic neo-plasms/proliferations or extrahepatic neoplasms seen in children and young adults. Finally, FISH testing can be used as a diagnostic tool to confirm the diagnosis of FL-HCC, in the appropriate clinical setting.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Acute Myeloid Leukemia (AML) with KMT2A rearrangements (KMT2Ar), found on chromosome 11q23, is often called KMT2A-rearranged AML (KMT2Ar-AML). This variant is highly aggressive, characterized by rapid disease progression and poor outcomes. Growing knowledge of epigenetic changes, especially lactylation, has opened new avenues for investigation and management of this subtype.
View Article and Find Full Text PDFBiochemistry
January 2025
Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland.
Janustatin A is a potently cytotoxic polyketide alkaloid produced at trace amounts by the marine bacterial plant symbiont . Its biosynthetic terminus features an unusual pyridine-containing bicyclic system of unclear origin, in which polyketide and amino acid extension units appear reversed compared to the order of enzymatic modules in the polyketide synthase (PKS)-nonribosomal peptide synthetase (NRPS) assembly line. To elucidate unknown steps in heterocycle formation, we first established robust genome engineering tools in .
View Article and Find Full Text PDFRev Esp Enferm Dig
January 2025
Gastroenterology, Meizhou People's Hospital. Meizhou Academy of Medical Sciences, China.
A 32-year-old man had recurrent abdominal pain and vomiting for 2 weeks. Physical examination revealed a 4×2-cm abdominal tough mass with unclear boundaries. Palpation caused mild tenderness without rebound pain.
View Article and Find Full Text PDFClin Transl Med
January 2025
Unit of Molecular Biology, Georges-François Leclerc Cancer center, UNICANCER, Dijon, France.
Background: Molecular diagnosis has become highly significant for patient management in oncology.
Methods: Here, 30 well-characterized clinical germline samples were studied with adaptive sampling to enrich the full sequence of 152 cancer predisposition genes. Sequencing was performed on Oxford Nanopore (ONT) R10.
Cureus
December 2024
Department of Neurology, International University of Health and Welfare Narita Hospital, Narita, JPN.
( gene rearrangement-positive small-cell lung cancer (SCLC) is extremely rare. A 73-year-old man was diagnosed with SCLC. Standard treatments were not effective.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!